Expectations from new products
Eli Lilly and Company (LLY) has launched various products under various franchises. Some of the new products include Portrazza, Cyramza, Basaglar, Jardiance, and Trulicity. Let’s look at these products and their expected performances in 1Q17.
Basaglar, an insulin glargine injection, was launched in US markets in December 2016. Analysts expect good growth for Basaglar’s 1Q17 revenues in the United States, Japan, and a few European markets.
Cyramza is an oncology drug used in the treatment of various forms of cancer. Sales for Cyramza are expected to rise in 1Q17 following increased demand for the drug in Japan and Europe, mainly for the treatment of metastatic NSCLC (non-small cell lung cancer) and metastatic colorectal cancer.
Jardiance is part of the Boehringer Ingelheim–Eli Lilly diabetes alliance. Jardiance’s revenues are expected to rise in 1Q17 following an increased demand for the drug in the United States.
Lartruvo, a drug for the treatment of advanced soft tissue sarcoma, was launched in the United States and Europe in 4Q16. The drug is expected to report positive quarter-over-quarter growth in 1Q17.
Portrazza, a drug for the treatment of NSCLC, is expected to report revenue growth in 1Q17, mainly due to higher sales in US markets.
Taltz is a new product launched in the United States and Europe in 2016. Analysts expect a strong performance for the drug in 1Q17, mainly in US markets.
Trulicity, a diabetes drug, is expected to report positive growth in revenues in 1Q17, mainly due to higher demand in US markets.
To divest the risk, you can consider ETFs such as the iShares US Healthcare (IYH), which holds 2.6% of its total assets in Eli Lilly (LLY), 2.1% in Biogen Idec (BIIB), 3.1% in Celgene (CELG), and 4.3% in Amgen (AMGN).